구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Antineoplastic Immune Cell |
Overview Company | Bristol-Myers Squibb |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lipid nanoparticle cancer vaccine platform delivering multiple STING activators for enhanced antit |
MoA Mechanism | targeting iron death, activating the cyclic Guanosine Monophosphate (GMP) and Adenosine Monophosphate (AMP) synthase-stimulator of interferon genes (STING protein) (cGAS-STING) signaling |
MoA Biomarker | biomarker landscape of CAFs in solid tumors, and systematically discuss how CAFs drive therapeutic resistance |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis) after switching were explored |
Toxicology CRS | Reported |
Clinical Safety signal | pneumonitis) after switching were explored |
Clinical Selected reported efficacy | ORR 19.2% |
Clinical Reported ORR | 19.2% |
Clinical Result source | ClinicalTrials.gov NCT02562755 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02562755 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Antineoplastic Immune Cell |
Overview Company | Bristol-Myers Squibb |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lipid nanoparticle cancer vaccine platform delivering multiple STING activators for enhanced antit |
MoA Mechanism | targeting iron death, activating the cyclic Guanosine Monophosphate (GMP) and Adenosine Monophosphate (AMP) synthase-stimulator of interferon genes (STING protein) (cGAS-STING) signaling |
MoA Biomarker | biomarker landscape of CAFs in solid tumors, and systematically discuss how CAFs drive therapeutic resistance |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis) after switching were explored |
Toxicology CRS | Reported |
Clinical Safety signal | pneumonitis) after switching were explored |
Clinical Selected reported efficacy | ORR 19.2% |
Clinical Reported ORR | 19.2% |
Clinical Result source | ClinicalTrials.gov NCT02562755 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02562755 |
추천 비교
추천 비교